Alle Storys
Folgen
Keine Story von EvaluatePharma Ltd mehr verpassen.

EvaluatePharma Ltd

EP Vantage Wins Commentator of the Year Award at European Mediscience Awards 2011

London (ots/PRNewswire)

EP Vantage, part of EvaluatePharma, was presented with the coveted Commentator of the Year Award at the European Mediscience Awards, sponsored by Matrix, on June 22, 2011.

The award, which honours clear and concise commentary in the pharma and biotech sector, can be given to analysts, journalists, columnists, research houses or specialist websites dedicated to providing sharp, perceptive and penetrating commentary.

The EP Vantage team - Lisa Urquhart, Amy Brown, Christian Glennie and Jonathan Gardner - beat a strong field that included analysts and fellow journalists to claim the prize.

Speaking about the achievement Jonathan de Pass, chief executive of EvaluatePharma, said: "I'm thrilled that the EP Vantage team have won the European Mediscience 2011 Commentator of the Year award.

The life-science industry is well served for commentary by several long-established publications and by many securities analysts so this is all the more an incredible achievement given that EP Vantage has been going for less than four years. After twice being runners-up for this award, this is well-deserved recognition for the team."

Notes for Editors:

About EP Vantage

Launched in 2007 by EvaluatePharma, EP Vantage is a daily online comment and analysis service providing insightful, forward-looking financial analysis of regulatory and patent decisions, marketing approvals, licensing deals, and M&A in the biotech and pharma industry.

Written by an experienced team of journalists, EP Vantage prides itself on covering market catalysts weeks and even months ahead of other industry sources.

EP Vantage's analysis is powered by EvaluatePharma, the leaders in consensus forecasts in the pharmaceutical industry for over 12 years.

EP Vantage editorial team

Lisa Urquhart, Editor

A financial journalist for over 11 years, Lisa joined EP Vantage in 2007 as editor. Prior to this she spent seven years at the Financial Times working in a variety of roles including Biotechnology Correspondent. During her time at the FT Lisa generated a number of exclusives, including Barr's $2.2bn takeover of Pliva. Lisa has overseen the successful launch of EP Vantage and guided its strategic development to create an award-winning comment and analysis service. Nominated for the third consecutive year, EP Vantage received the European MediScience Awards Commentator of the Year award in 2011.

Amy Brown, Senior Reporter

Amy joined EP Vantage from Thomson Financial News, where she covered the European pharmaceutical and biotechnology sectors for several years. She has extensive experience working as a financial journalist, working for companies including Bloomberg News, and has been a contributor to publications such as Corporate Financier. Amy's keen sense for news, highly analytical mind and writing ability have all contributed to the growing recognition and respect EP Vantage has commanded.

Christian Glennie, Senior Editorial Analyst

Christian joined EP Vantage from EvaluatePharma, where he worked as an analyst for seven years, developing extensive and in-depth knowledge of the pharmaceutical industry. Previously responsible for generating forecast models for over 60 pharma and biotech companies, Christian provides analysis and insight for EP Vantage content and is also an invaluable part of the writing team.

Jonathan Gardner, Reporter

Jonathan was previously a freelance journalist on a number of healthcare titles including Elsevier Global Medical News. Prior to this he was communications manager at US publication Health Affairs Journal and bureau chief for Modern Healthcare magazine. Jonathan brings a wealth of experience in both the US primary healthcare market and regulatory affairs to EP Vantage, extending the reach of the publication.

http://www.epvantage.com

About the European Mediscience Awards

The European Mediscience Awards Dinner, sponsored by Matrix, is the largest annual gathering of quoted biotech and life sciences companies in Europe. It celebrates the best in the sector and highlights the achievements of individuals and companies. The event recognises the importance of access to the capital markets to fund growth and innovation and is attended by specialist investors, advisors, media and analysts.

Now it is 10th year, the winners were announced at a dinner which was held at the Hotel Intercontinental, London W1 on Wednesday 22 June 2011.

http://www.mediscience-event.co.uk/winners/

Contact Lisa Urquhart EP Vantage Editor T: +44(0)20-7539-1819 E: lisau@epvantage.com EP Vantage 11-29 Fashion Street London E1 6PX United Kingdom Andrew Beaven Marketing Director, EvaluatePharma Ltd T: +44(0)20-7539-1818 E: andrewb@evaluatepharma.com EvaluatePharma Ltd 11-29 Fashion Street London E1 6PX United Kingdom

Contact:

.

Weitere Storys: EvaluatePharma Ltd
Weitere Storys: EvaluatePharma Ltd
  • 02.02.2011 – 16:14

    Pharmaceutical Industry Bracing for Record Patent Expiries, EvaluatePharma Data Reveals

    London (ots/PRNewswire) - Thirteen US blockbusters will lose patent protection over the next two years, data from EvaluatePharma show, highlighting the challenges facing the pharmaceutical industry in the coming years. With the reporting season in full swing it is no wonder that several big pharmaceutical company chief executives have warned of tough times ahead. ...

  • 03.05.2010 – 06:03

    Pfizer Reigns Supreme After Patent Cliff as Humira Kicks Avastin off Top Spot

    London, May 3, 2010 (ots/PRNewswire) - The rheumatoid arthritis treatment Humira will replace Lipitor as the world's biggest-selling drug in 2016, but a familiar name, Pfizer, will still be the biggest seller of medicines after the patent cliff according to the World Preview 2016 report published today by EvaluatePharma, the premier provider of pharma and biotech ...